Skip Nav Destination
![]()
You do not currently have access to this content.
PRISM Shows Power of Personalized Medicine in Kids
July 23, 2024
PRISM trial researchers found that 36% of children with high-risk pediatric cancers who receive precision-guided therapy responded to the treatment. In addition, patients had a significantly higher rate of progression-free survival after 2 years than those who received standard of care or molecularly unguided treatment.
RSS Feeds